75 research outputs found
Nadroparine-induced skin necrosis on a patient with essential thrombocythaemia: a case report
Skin necrosis is a rare but serious complication of subcutaneously administered low-molecular-weight heparin. We report a case of a 53-year-old female patient with skin necrosis induced by subcutaneous administration of nadroparine. The patient suffered from essential thrombocythaemia on a background of chronic myeloproliferative disease. She was admitted to our clinic with a subacute ileus due to endometriosis of the rectosigmoid junction. She underwent a high anterior resection and she received pre- and postoperative antithrombotic prophylaxis with subcutaneous nadroparine on a daily basis. On the 6th and 7th postoperative days, two skin necroses occurred at two injection sites
Improving the robustness to input errors on touch-based self-service kiosks and transportation apps
acceptedVersio
A multicenter clinical evaluation of the Clot Signature Analyzer
Background :âThe Clot Signature Analyzer (CSA) was designed to assess global hemostasis as a screening assay using non-anticoagulated whole blood. Three different measurements are produced by the instrument: platelet hemostasis time (PHT), clot time (CT), and collagen-induced thrombus formation (CITF). Objectives :âThe purpose of the present study was to determine normal ranges for these measurements and assess the performance of the CSA in patients with well-characterized hemostatic disorders and in normal subjects. Patients and methods :âFour institutions participated in the study. Each established their own normal reference ranges. Patients with well-characterized hemostatic disorders and concurrent normal controls were subsequently examined. Results :âNormal ranges between institutions were similar although statistically different. One hundred and eight patients were examined: 46 individuals with von Willebrand disease (VWD) (type 1, 26; type 2A, 11; type 2B, six; type 3, three); 38 patients with a coagulation factor deficiency; 13 individuals with platelet function defects; 10 patients taking warfarin; and one individual on low-molecular-weight heparin. Of these patients, 89% had at least one abnormality by CSA: 42/46 VWD patients, 35/38 coagulation protein defect patients, 9/13 patients with platelet function defects, 9/10 patients on warfarin and 1/1 patient on low-molecular-weight heparin. Of 116 normal subjects, 103 (89%) fell within the centers' normal range. These data suggest that the CSA has a good sensitivity for bleeding disorders.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/73054/1/j.1538-7836.2004.00695.x.pd
A interprofissionalidade no combate a violĂȘncia sexual infantil: um relato de experiĂȘncia do PET-SaĂșde-Interprofissionalidade
Introdução: O interesse sexual de um ou mais adultos em relação a uma criança ou adolescente Ă© denominado como abuso sexual, e pode ocorrer tanto no ambiente intrafamiliar quanto no meio extrafamiliar.1 Dados da Organização Mundial da SaĂșde (OMS) estimam que ao redor do mundo, em torno de 7-36% das meninas e 3-29% dos meninos sofreram algum tipo de abuso sexual na infĂąncia. Embora elevadas, as estatĂsticas sĂŁo subestimadas, dada a construção do âmuro do silĂȘncioâ da qual participam familiares e atĂ© profissionais da saĂșde resultando em encobertamente da violĂȘncia.2 As potenciais consequĂȘncias no desenvolvimento infanto-juvenil acometem o Ăąmbito fĂsico, psĂquico, social, sexual e outros.1 Objetivo: Relatar a experiĂȘncia de acadĂȘmicas em uma ação sobre combate Ă violĂȘncia sexual infantil para alunos do quinto ano do Ensino Fundamental II. Metodologia: Trata-se de um relato de experiĂȘncia realizado por acadĂȘmicas do curso de medicina e farmĂĄcia que compĂ”em o grupo PET-SaĂșde-Interprofissionalidade do municĂpio de TrĂȘs Lagoas - Mato Grosso do Sul, com a participação de uma psicĂłloga e uma educadora social do Centro de ReferĂȘncia Especializado de AssistĂȘncia Social (CREAS). Resultados: Dada a importĂąncia do tema, as acadĂȘmicas solicitaram o auxĂlio das profissionais do CREAS para abordagem do assunto a fim de fornecer qualidade na transmissĂŁo de informaçÔes e didĂĄtica adequada. A princĂpio, abordou-se os aspectos comportamentais naturais da infĂąncia e adolescĂȘncia, em seguida frases comumente ditas por abusadores, tipos de abusos e sinais tĂpicos de crianças que sofreram algum tipo de violĂȘncia como, por exemplo, o isolamento social, estigmatização, vergonha, medo, ansiedade, depressĂŁo.2 As crianças e adolescentes do sexo feminino sĂŁo as vĂtimas predominantes nesse tipo de violĂȘncia, que ocorre principalmente no ambiente domĂ©stico3, dados demonstrados por meio de depoimentos dos alunos Ă s acadĂȘmicas. AtravĂ©s do olhar das discentes, e das experiĂȘncias compartilhadas a partir do vĂnculo criado com profissionais e crianças da escola, sĂŁo inĂșmeras as situaçÔes que predispĂ”em a perpetuação desse tipo de violĂȘncia, tais como pouco diĂĄlogo com pais e responsĂĄveis sobre o assunto e alta exposição Ă s mĂdias sociais. Nesta experiĂȘncia foi possĂvel observar que o agressor geralmente possui proximidade com a vĂtima, estabelecendo uma relação de confiança e afeto com a criança, o que gera sentimentos de dĂșvidas na vĂtima, a qual nĂŁo Ă© capaz de discernir demonstraçÔes de afeto e o abuso sexual.1 A ação auxiliou a instruir sobre como e para quem pedir ajuda, fortalecendo o vĂnculo entre o jovem e a escola e com Unidades BĂĄsicas de SaĂșde. ConsideraçÔes Finais: A intervenção na escola unindo de forma interprofissional e intersetorial ĂĄreas da saĂșde e a assistĂȘncia social Ă© um importante instrumento no combate a violĂȘncia sexual infantil.
Palavras-chave: Adolescente. ViolĂȘncia Sexual. Educação interprofissional
Objective structured assessment of technical competence in transthoracic echocardiography: a validity study in a standardised setting
Loss-of-function mutations in SLC30A8 protect against type 2 diabetes.
NeĂ°st ĂĄ sĂĂ°unni er hĂŠgt aĂ° nĂĄlgast greinina Ă heild sinni meĂ° ĂŸvĂ aĂ° smella ĂĄ hlekkinn View/OpenLoss-of-function mutations protective against human disease provide in vivo validation of therapeutic targets, but none have yet been described for type 2 diabetes (T2D). Through sequencing or genotyping of ~150,000 individuals across 5 ancestry groups, we identified 12 rare protein-truncating variants in SLC30A8, which encodes an islet zinc transporter (ZnT8) and harbors a common variant (p.Trp325Arg) associated with T2D risk and glucose and proinsulin levels. Collectively, carriers of protein-truncating variants had 65% reduced T2D risk (P = 1.7 Ă 10(-6)), and non-diabetic Icelandic carriers of a frameshift variant (p.Lys34Serfs*50) demonstrated reduced glucose levels (-0.17 s.d., P = 4.6 Ă 10(-4)). The two most common protein-truncating variants (p.Arg138* and p.Lys34Serfs*50) individually associate with T2D protection and encode unstable ZnT8 proteins. Previous functional study of SLC30A8 suggested that reduced zinc transport increases T2D risk, and phenotypic heterogeneity was observed in mouse Slc30a8 knockouts. In contrast, loss-of-function mutations in humans provide strong evidence that SLC30A8 haploinsufficiency protects against T2D, suggesting ZnT8 inhibition as a therapeutic strategy in T2D prevention.US National Institutes of Health (NIH) Training
5-T32-GM007748-33
Doris Duke Charitable Foundation
2006087
Fulbright Diabetes UK Fellowship
BDA 11/0004348
Broad Institute from Pfizer, Inc.
NIH
U01 DK085501
U01 DK085524
U01 DK085545
U01 DK085584
Swedish Research Council
Dnr 521-2010-3490
Dnr 349-2006-237
European Research Council (ERC)
GENETARGET T2D
GA269045
ENGAGE
2007-201413
CEED3
2008-223211
Sigrid Juselius Foundation
Folkh lsan Research Foundation
ERC
AdG 293574
Research Council of Norway
197064/V50
KG Jebsen Foundation
University of Bergen
Western Norway Health Authority
Lundbeck Foundation
Novo Nordisk Foundation
Wellcome Trust
WT098017
WT064890
WT090532
WT090367
WT098381
Uppsala University
Swedish Research Council and the Swedish Heart- Lung Foundation
Academy of Finland
124243
102318
123885
139635
Finnish Heart Foundation
Finnish Diabetes Foundation, Tekes
1510/31/06
Commission of the European Community
HEALTH-F2-2007-201681
Ministry of Education and Culture of Finland
European Commission Framework Programme 6 Integrated Project
LSHM-CT-2004-005272
City of Kuopio and Social Insurance Institution of Finland
Finnish Foundation for Cardiovascular Disease
NIH/NIDDK
U01-DK085545
National Heart, Lung, and Blood Institute (NHLBI)
National Institute on Minority Health and Health Disparities
N01 HC-95170
N01 HC-95171
N01 HC-95172
European Union Seventh Framework Programme, DIAPREPP
Swedish Child Diabetes Foundation (Barndiabetesfonden)
5U01DK085526
DK088389
U54HG003067
R01DK072193
R01DK062370
Z01HG000024info:eu-repo/grantAgreement/EC/FP7/20201
- âŠ